GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » PB Ratio

DICE Therapeutics (DICE Therapeutics) PB Ratio : 4.38 (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is DICE Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), DICE Therapeutics's share price is $47.55. DICE Therapeutics's Book Value per Share for the quarter that ended in Jun. 2023 was $10.86. Hence, DICE Therapeutics's PB Ratio of today is 4.38.

The historical rank and industry rank for DICE Therapeutics's PB Ratio or its related term are showing as below:

DICE' s PB Ratio Range Over the Past 10 Years
Min: 1.78   Med: 3.47   Max: 6.16
Current: 4.38

During the past 4 years, DICE Therapeutics's highest PB Ratio was 6.16. The lowest was 1.78. And the median was 3.47.

DICE's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs DICE: 4.38

During the past 12 months, DICE Therapeutics's average Book Value Per Share Growth Rate was 49.30% per year.

Back to Basics: PB Ratio


DICE Therapeutics PB Ratio Historical Data

The historical data trend for DICE Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DICE Therapeutics PB Ratio Chart

DICE Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
PB Ratio
- - 3.09 2.63

DICE Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 2.97 2.63 2.50 4.28

Competitive Comparison of DICE Therapeutics's PB Ratio

For the Biotechnology subindustry, DICE Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DICE Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DICE Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where DICE Therapeutics's PB Ratio falls into.



DICE Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

DICE Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2023)
=47.55/10.861
=4.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


DICE Therapeutics  (NAS:DICE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


DICE Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of DICE Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DICE Therapeutics (DICE Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
400 East Jamie Court, Suite 300, South San Francisco, CA, USA, 94080
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Executives
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
John R. Jacobsen officer: CSO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Scott M. Robertson officer: CFO & CBO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Lu Timothy officer: CMO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Kevin Judice director, officer: CEO 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Lisa Bowers director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Mittie Doyle director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Michael P. Rubin 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Shaan-chirag C Gandhi director NORTHPOND VENTURES, 7500 OLD GEORGETOWN ROAD, BETHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Stephen Zachary director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902